“Generic Medicines in the Taiwanese and German Legal Systems” 03 June 2011 in Taipei, Taiwan Role of Generics in the German Health Care System Financial.

Slides:

Advertisements

Similar presentations

Pharmaceutical Policy and Pricing: How are Countries Getting Greater Value? Commonwealth Fund/ Alliance for Health Reform Briefing on Capitol Hill Dr.

Advertisements

The 'Zurich Model' – a market-based approach to health care reform Dr. Ulrike Götting VFA - German Association of Research-Based Pharmaceutical Companies.

What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.

Current situation at the insurance market in Hungary (system of covering ST by insurance companies, perspectives, suggested strategies) dr Choma Balázs.

The critical role of Evolving Information Systems and the need for Standardised Coding.

Reducing the costs of medicine by dispensing generic medicine 25 September 2013 Presented by: Christo Rademan – Managing Director.

International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 22, 2005.

H.B. Fuller Company 2009 Open Enrollment: Helping you Buy Well, Use Well, Be Well October, 2008.

Canadian Generic Pharmaceutical Association Getting to the Heart of Drug Sustainability – The Issues Canada’s Public Policy Forum - Atlantic Summit On.

Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences

The German Health Care System and the Federal Joint Committee (G-BA) Norbert Schmacke FJC/ University of Bremen.

Peter EichlerChart 1 Private Health Insurance with a Focus on the Austrian Modell.

Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)

Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.

3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.

Current Approaches in European Health Care Policy What models can balance the needs of payors and industry?

Copay Structure Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.

Facts and Figures 2008 Medicines and Health Care The Norwegian Association of Pharmaceutical Manufacturers (LMI)

Karmen Hanson, MA Senior Policy Specialist National Conference of State Legislatures 340B Drug Purchasing: Options for States Overview of State Rx & 340B.

Healthcare Reforms and Pharmaceuticals Lessons from Turkey Prof. Dr. Mehtap Tatar Hacettepe University Faculty of Economics and Administrative Sciences.

EHA Early Retiree Plan Benefit Options.

National Health Insurance - UHC 29 SEPTEMBER 2014 Anban Pillay Deputy Director General National Department of Health South Africa

The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.

Universal Coverage… “Pharmaceutical Benefit Management” or “Pharmacy Benefit Management” is the set of rules, controls and enforcement tools that define.

Financial Issues Chapter 14 Start Quiz. In 1985 the average prescription price was approximately $10. By 2011 what did the average prescription price.

LIST OF DRUGS COVERED BY HEALTH INSURANCE FUND OF THE REPUBLIC OF MACEDONIA Ms. Maja Parnardzieva – Zmejkova, MSc, CEO October 2011.

The Insurance Contract Section Understanding Business and Personal Law The Insurance Contract Section 35.1 Insurance Protection What Is Insurance?

The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.

The Pharmaceutical Industry in Turkey

Drug Prices in Canada and the US: More Than Meets the Eye? National Academy of Social Insurance Annual Conference Wayne Critchley Executive Director, PMPRB.

Health Insurance Coverage Premium Increase - 16% 2008 Premium Increase - 0.0% 2009 Premium Increase - 0.0% 2010 Premium Increase - 2.0% 2011.

TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.

1 Working Together for a New Foundation Pharmacy Solutions in Drug Plan Management October 22, 2014 Gary Coles, SVP, Group Administration.

Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.

FINANCIAL ISSUES CHAPTER 14. CHAPTER OUTLINE Financial Issues Third-Party Programs – private health insurance – managed care programs – public health.

Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 System of counting of reimbursement costs in the Czech Republic Tomas Sechser.

The Health Care System in Germany – a Dinosaur in Perpetual Change Dominik Naumann – presentation made by Eckhard Metze Confederation of German Employer.

New Analysis of DRE Savings for States & Federal Government September 22, 2008.

(Fortune, 2002, p. 16).  Competition  Barriers to Entry  Regulation.

Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.

Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 Monitoring of doctor´s prescription in the Czech Republic Tomas Sechser Daniela.

By Jeff Kennedy September 21,  Increased hospital mergers ◦ Insurers need to offset hospitals bargaining power ◦ Affordable Care Act  Nationwide.

Health Insurance Plans 2.4 Cost is a major concern Health care is over 15% of the gross national product Without insurance the cost of an illness can become.

October Warsaw1 Price Volume Agreements in Hungary National Health Insurance Fund Administration (OEP) Pharmaceutical Department Tamás Kovacs.

French Healthcare vs. American Healthcare By: Meghan Rocheleau a.k.a. Madeleine.

Managed Care Pharmacy Financials January 15, 2015.

Drug Formulary Development & Management

How Pharmacy Benefit Managers Work April 28, 2016 Producer: Alexander Perry Director: Afzal Bari.

Pharmacy Benefit Management (PBM) 101

Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.

MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.

Financial Issues Chapter 14. Financial Issues Financial issues have a substantial influence on health care and pharmacy practice. In 1985 the average.

Formulary Manufacturer Contracting Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2015.

School of Public Health Health Economics and Health Care Management University of Bielefeld Bielefeld (Germany), September 29th, 2015 Prof. Dr. Wolfgang.

M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.

The Czech Health System – its Presence and Future

Managed Care Models: The Benefit vs. Cost Balance

Personal Finance Health Insurance

The Basics of Pharmacy Benefit Management (PBM)

The German Health Care System and the Federal Joint Committee (G-BA)

Health Technology Assessment

Health System in Germany

Offering Employer Options & Value from UNICARE of Arkansas

Germany’s Approach to Prescription Drug Pricing

Private Insurance 2008–2012: Change in Average Use and Prices

Pharmacy Benefit Manager

Drug Formulary Development & Management

Germany’s Approach to Prescription Drug Pricing

Presentation transcript:

“Generic Medicines in the Taiwanese and German Legal Systems” 03 June 2011 in Taipei, Taiwan Role of Generics in the German Health Care System Financial Impacts and Implementation Measures Silke Baumann Federal Ministry of Health (Germany)

Introduction The German Health Care System

Otto von Bismarck ( ) 1883: 1st act on Statutory Health Insurance (SHI) pay-as-you-go principle proportional contributions from insurees and their employers self-governmental structures to operate the sickness funds and decide about benefit coverage beyond the legally defined scope

Germany‘s Health Care System Today

source: Federal Ministry of Health/KV45

Share of Drugs in Total SHI-Spendings source: Federal Ministry of Health/KJ 1

SHI-spendings on drugs 1994 – 2009 in billion Euro source: Federal Ministry of Health/KJ 1

Drug Supply in the Statutory Health Insurance

Access to Drugs out-patient care: reimbursement by SHI in-patient care: drugs covered by hospitals (DRGs) market authorisation (proof of quality, safety and efficacy) cost-containing instruments by law no further legal restrictions

market authorisation reimbursement by SHI (price set by producer) Drug supply in the out-patient sector exclusion by law life style drugs OTC G-BA guidelines exclusion or restriction reimbursement amounts therapy advice... co-payment 10 %, min 5 €, max. 10 € release is possible individual limits limitations of reimbursement => cost containment

Cost Containment and the Role of Genenics in Germany

Share of Generics 2009 (prescriptions)

source: AVR/WIdO

Average Price per DDD

Cost Containment Measures

Fixed Reimbursement Amounts 2 steps: 1.Clustering of pharmaceutical substances by the Federal Joint Committee èsame active ingredient (ATC 5) ètherapeutic equivalence (ATC 4) 2.Establishing reimbursement amounts by Federal Association of Sickness Funds Price-Level: maximum price at lowest third of price range

Effects of Reimbursement Amounts è most companies lower their prices to the reimbursement amount (or even lower) è if not: losing of market share è SHI spendings: stable for drugs subject to reimbursement amounts

Market Share: with/without Reimbursement Amounts 2009 source: Insight Health

Individual Rebates/Tendering è Sickness funds are allowed to tender for rebates on drugs è Producers can contract with sickness funds rebates vs. higher sales quantity è share of generics (presciption volume): 96 % (source: ProGenerika ) è savings in 2010: approx. 1 Bill. Euro

Substitution of Drugs prescribtion by INN or by brand name (original or generic) INN brand name pharmacy hands out one of the 3 cheapest products pharmacy hands out the prescribed product or one of the 3 cheapest ones rebate contract NO rebate contract pharmacy hands out a rebated product PHARMACY

Release from Co-Payment è Patients‘ co-payment: u 10 % of the price u min. 5 Euro u max. 10 Euro è Release from co-payment for drugs with price at least 30 % lower than fixed reimbursement amount

Price-index January 2005 – May 2007

Cost-containment Instruments è fixed reimbursement amounts è „aut-idem“ (substitution) è individual rebates/tendering è release of co-payment è prescription controlling è no access to physician-related priscibing data for industry è no manipulated software for pysicians è no free drugs for pharmacies è...

source: AVR/WIdO

Silke Baumann Federal Ministry of Health Germany Thank you for your attention!